Evidence map›Paper›PMID 41276558›Full record

ArticleScientific reports2025

Fe₃O₄@MCM-41-Cystine-ZnCl₂ nanocomposite in deep eutectic solvent: a sustainable and scalable catalytic system for three-component synthesis of triarylpyridines.

Rima Heider Al Omari, Reza Mohammadi, Subbulakshmi Ganesan, Hasnaawei Al-Shaker, Karthikeyan Jayabalan, Renu Sharma, Aashna Sinha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rima Heider Al OmariFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Reza MohammadiDepartment of Chemistry, Young Researchers and Elite Club, Tehran Branch, Islamic Azad University, Tehran, Iran. rmohammadichem@gmail.com.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Hasnaawei Al-ShakerCollege of Pharmacy, The Islamic University, Najaf, Iraq.
Karthikeyan JayabalanDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Renu SharmaDepartment of Chemistry, University Institute of Sciences, Chandigarh University, Mohali, Punjab, India.
Aashna SinhaSchool of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, we report a novel Fe₃O₄@MCM-41-Cystine-ZnCl₂ nanocatalyst as a highly active, recyclable, and sustainable platform for the synthesis of triarylpyridines. This catalyst integrates the benefits of a mesoporous MCM-41 support, magnetic Fe₃O₄ core, and ZnCl₂ Lewis acid centers stabilized by cystine linkers, resulting in high surface area, strong catalytic activity, and excellent stability. Under optimized conditions (100 °C, 2 h, 7 mol% catalyst) in a deep eutectic solvent (choline chloride-glycerol), twenty triarylpyridines were obtained in excellent yields (84-98%). The system exhibited broad substrate tolerance, efficiently converting electron-donating, electron-withdrawing, sterically hindered, and heteroaryl substrates with consistent turnover numbers (TON = 12.0-14.0) and turnover frequencies (TOF = 6.0-7.0 h⁻

Indexed as

Deep eutectic solvent (DES)Fe₃O₄@MCM-41-Cystine-ZnCl₂ nanocompositeMagnetic catalystSustainable synthesisTriarylpyridines

Identifiers

PMID41276558
PMCPMC12749168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.